Drug name - Zydelig

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44638 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Aug, 2025

(2 years from now)

US8865730 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(10 years from now)

US10730879 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(10 years from now)

US9469643 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Sep, 2033

(10 years from now)

CN102229609A GILEAD SCIENCES INC Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
Mar, 2013

(9 years ago)

CN104334560A GILEAD SCIENCES INC (S) -2-(1 - (9H - -6 - Ylamino) Propyl) -5--3 - Phenyl - -4 (3H) - Ketone Of Polymorph
Mar, 2017

(5 years ago)

CN106146506A GILEAD SCIENCES INC Polymorph Of (S)-2-(1-(9H-Purine-6-Ylamino)Propyl)-5-Fluorin-3-Phenyl Quinazoline-4(3H) Ketone
Apr, 2018

(4 years ago)

CN101031569B GILEAD SCIENCES INC As Human Phosphatidylinositol 3- Delta Inhibitor Quinazolinone
May, 2025

(2 years from now)

CN101031569A GILEAD SCIENCES INC Quinazolones As Human Phosphoinositide 3-Kinase Delta Inhibitor
May, 2025

(2 years from now)

EP2612862A3 GILEAD SCIENCES INC Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
May, 2025

(2 years from now)

EP2612862A2 GILEAD SCIENCES INC Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
May, 2025

(2 years from now)

EP3153514A1 GILEAD SCIENCES INC Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
May, 2025

(2 years from now)

EP2612862B1 GILEAD SCIENCES INC Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
May, 2025

(2 years from now)

EP3153514B1 GILEAD SCIENCES INC Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
May, 2025

(2 years from now)

EP1761540A1 GILEAD SCIENCES INC Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
May, 2025

(2 years from now)

EP1761540B1 GILEAD SCIENCES INC Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
May, 2025

(2 years from now)

EP2834241B1 GILEAD SCIENCES INC Polymorphic Forms Of (S)-2-(1-(9H-Purin-6-Ylamino)Propyl)-5-Fluoro-3-Phenylquinazolin-4(3H)-One
Mar, 2033

(10 years from now)

EP2834241A1 GILEAD SCIENCES INC Polymorphic Forms Of (S)-2-(1-(9H-Purin-6-Ylamino)Propyl)-5-Fluoro-3-Phenylquinazolin-4(3H)-One
Mar, 2033

(10 years from now)

EP2834241A4 GILEAD SCIENCES INC Polymorphic Forms Of (S)-2-(1-(9H-Purin-6-Ylamino)Propyl)-5-Fluoro-3-Phenylquinazolin-4(3H)-One
Mar, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980901 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta May, 2025

(2 years from now)

US9149477 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta May, 2025

(2 years from now)

USRE44599 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta Jul, 2025

(2 years from now)

US9492449 GILEAD SCIENCES INC Therapies for hematologic malignancies Mar, 2030

(7 years from now)

Drugs and Companies using IDELALISIB ingredient

Treatment: For the treatment of patients with cll, fl, or sll; Inhibition on pi3k kinase; For the treatment of patients with cll, fl, or sll; for the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.